Skip to main content
OpenTrials
Completed

NCT Number: NCT04996043

Efficacy Testing of Collagen Peptide Drink

To assess Collagen Peptide Drink on skin condition improvement

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Condition Skin Diseases Skin and Connective Tissue Diseases

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chia Nan University of Pharmacy ＆ Science

Tainan, 71710, Taiwan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults aged above 20 years old

Exclusion criteria

  • Subject who is not willing to participate in this study.
  • Patients with diseases of the skin, liver, kidney.
  • Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder.
  • Female who is pregnant or nursing or planning to become pregnant during the course of the study.
  • Received facial laser therapy, chemical peeling or UV overexposure in the past 4 weeks.
  • Constant drug use
  • Participated cosmetic product human study in the past 3 months.

Treatment and study plan

Collagen Peptide Drink

Dietary Supplement

Testing product

Other names: Pearlosophy-Collagen Peptide Drink

Placebo drink

Dietary Supplement

Blank

Primary outcomes

  1. The change of skin wrinkles

    Time frame: Change from Baseline skin wrinkles at 4 weeks

    VISIA Complexion Analysis System was utilized to measure skin wrinkles. Units: arbitrary units

  2. The change of skin texture

    Time frame: Change from Baseline skin texture at 4 weeks

    VISIA Complexion Analysis System was utilized to measure skin texture. Units: arbitrary units

  3. The change of skin collagen density

    Time frame: Change from Baseline skin collagen density at 4 weeks

    DermaLab® Series SkinLab Combo was utilized to measure skin pores. Units: arbitrary units

  4. The change of skin elasticity

    Time frame: Change from Baseline skin elasticity at 4 weeks

    Soft Plus was utilized to measure skin elasticity. Units: arbitrary units

  5. The change of MMP-1 of blood

    Time frame: Change from Baseline MMP-1 at 4 weeks

    Venous blood was sampled to measure MMP-1

  6. The change of TIMP-1 of blood

    Time frame: Change from Baseline TIMP-1 at 4 weeks

    Venous blood was sampled to measure TIMP-1

Secondary outcomes

  1. The change of skin melanin index

    Time frame: Change from Baseline skin melanin index at 4 weeks

    Soft Plus was utilized to measure skin melanin index. Units: arbitrary units

  2. The change of skin L* value

    Time frame: Change from Baseline L* value at 4 weeks

    Chroma Meter MM500 was utilized to measure skin L* value. Units: arbitrary units, 0-100

  3. The change of skin spots

    Time frame: Change from Baseline skin spots at 4 weeks

    VISIA Complexion Analysis System was utilized to measure skin spots. Units: arbitrary units

  4. The change of skin UV spots

    Time frame: Change from Baseline skin UV spots at 4 weeks

    VISIA Complexion Analysis System was utilized to measure skin UV spots. Units: arbitrary units

  5. The change of skin brown spots

    Time frame: Change from Baseline skin brown spots at 4 weeks

    VISIA Complexion Analysis System was utilized to measure skin brown spots. Units: arbitrary units

  6. The change of TNF-α of blood

    Time frame: Change from Baseline TNF-α at 4 weeks

    Venous blood was sampled to measure TNF-α

  7. The change of IL-10 of blood

    Time frame: Change from Baseline IL-10 at 4 weeks

    Venous blood was sampled to measure IL-10

  8. The change of SOD-RBC of blood

    Time frame: Change from Baseline SOD-RBC at 4 weeks

    Venous blood was sampled to measure SOD-RBC

  9. The change of f-thiols of blood

    Time frame: Change from Baseline f-thiols at 4 weeks

    Venous blood was sampled to measure f-thiols

  10. The change of t-GSH of blood

    Time frame: Change from Baseline t-GSH at 4 weeks

    Venous blood was sampled to measure t-GSH

  11. The change of GST-RBC of blood

    Time frame: Change from Baseline GST-RBC at 4 weeks

    Venous blood was sampled to measure GST-RBC

  12. The change of MDA of blood

    Time frame: Change from Baseline MDA at 4 weeks

    Venous blood was sampled to measure MDA

  13. The change of skin moisture

    Time frame: Change from Baseline skin moisture at 4 weeks

    Corneometer® CM825 was utilized to measure skin moisture. Units: arbitrary Corneometer® units 0-120

  14. The change of blood total antioxidant capacity (TAC)

    Time frame: Change from Baseline TAC at 4 weeks

    Venous blood was sampled to measure concentrations of TAC

Other outcomes

  1. The change of total cholesterol of blood

    Time frame: Change from Baseline total cholesterol at 4 weeks

    Venous blood was sampled to measure total cholesterol

  2. The change of triglyceride of blood

    Time frame: Change from Baseline triglyceride at 4 weeks

    Venous blood was sampled to measure triglyceride

  3. The change of SGOT of blood

    Time frame: Change from Baseline SGOT at 4 weeks

    Venous blood was sampled to measure SGOT

  4. The change of SGPT of blood

    Time frame: Change from Baseline SGPT at 4 weeks

    Venous blood was sampled to measure SGPT

  5. The change of BUN of blood

    Time frame: Change from Baseline BUN at 4 weeks

    Venous blood was sampled to measure BUN

  6. The change of creatinine of blood

    Time frame: Change from Baseline creatinine at 4 weeks

    Venous blood was sampled to measure creatinine

  7. The change of uric acid of blood

    Time frame: Change from Baseline uric acid at 4 weeks

    Venous blood was sampled to measure uric acid

Sponsors and collaborators

Lead sponsor

TCI Co., Ltd.

Industry

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Aug 9, 2021
Registry last updated
Jan 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.